Stroke. 2026 Mar;57(3):850-853. doi: 10.1161/STROKEAHA.125.053204. Epub 2026 Feb 23.
ABSTRACT
Variations in thrombus composition significantly influence the efficacy of conventional thrombolytic therapies in acute ischemic stroke. Emerging treatments, designed to target distinct components of the thrombus, are currently under evaluation and offer renewed hope for enhancing clot dissolution and improving clinical outcomes. This review will examine the current evidence surrounding glycoprotein IIb/IIIa inhibitors in the treatment of acute ischemic stroke, drawing on the latest randomised-controlled trials, identifying promising therapeutic candidates and evaluating the clinical contexts in which these agents are most likely to be beneficial.
PMID:41730038 | DOI:10.1161/STROKEAHA.125.053204